<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597399</url>
  </required_header>
  <id_info>
    <org_study_id>SPKRPE-PASS</org_study_id>
    <nct_id>NCT03597399</nct_id>
  </id_info>
  <brief_title>A Patient Registry Study for Patients Treated With Voretigene Neparvovec</brief_title>
  <official_title>A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect long-term safety information (i.e., for 5 years
      after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its
      subretinal injection procedure, the concomitant use of corticosteroids, or a combination of
      these procedures and products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Voretigene neparvovec-rzyl is a gene therapy intended for use in individuals with confirmed
      biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. Mutations in
      the RPE65 gene are associated with several clinical manifestations including nyctalopia,
      decreased visual field and decreased visual acuity. Voretigene neparvovec-rzyl uses a
      non-pathogenic recombinant adeno-associated virus vector serotype 2 (AAV2) to deliver cDNA
      encoding RPE65 protein to target cells in the retina. Voretigene neparvovec-rzyl is
      administered to each eye via subretinal injection. The administration of voretigene
      neparvovec-rzyl is recommended to be performed to each eye on separate days within a close
      interval. Prescribing information recommends an immunomodulatory regimen concomitant with
      administration, with the actual regimen dependent upon the dosing center.

      This post authorization safety study will focus on further characterizing the long-term
      safety profile of voretigene neparvovec-rzyl in patients with RPE65 mutation-associated
      retinal dystrophy using an observational, longitudinal design.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Collection of all Adverse Events and Serious Adverse Events</measure>
    <time_frame>up to 5 years</time_frame>
    <description>adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of Pregnancy Outcomes</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Follow pregnancy outcomes in participants (and female partners of male participants) who received voretigene neparvovec</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV2-hRPE65v2,voretigene neparvovec-rzyl</intervention_name>
    <description>Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.</description>
    <other_name>AAV2-hRPE65v2</other_name>
    <other_name>voretigene neparvovec</other_name>
    <other_name>gene therapy vector</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals who received voretigene neparvovec-rzyl in at least one eye.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Received voretigene neparvovec-rzyl in at least one eye.

          2. Signed informed consent/assent (when applicable). These are obtained as required under
             institutional policies and applicable laws and regulations unless a consent waiver is
             obtained from the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).

        Exclusion Criteria:

        1. Previously participated in, or are currently participating in, a Spark Therapeutics
        clinical trial and received voretigene neparvovec-rzyl in both eyes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Ophthalmic Lead</last_name>
    <role>Study Director</role>
    <affiliation>Spark Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cullen Eye Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leber Congenital Amaurosis (LCA)</keyword>
  <keyword>Inherited Retinal Dystrophy</keyword>
  <keyword>RPE65</keyword>
  <keyword>Retinitis Pigmentosa (RP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

